Effect of metabolic syndrome on clinical outcomes of non‐diabetic peritoneal dialysis patients in <scp>I</scp>ndia

Prasad, Narayan; Sinha, Archana; Gupta, Amit; Sharma, Raj Kumar; Kaul, Anupama; Bhadauria, Dharmender; Ranagswamy, Dharshan

doi:10.1111/nep.12124

Cited by 12 publications

(9 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, although also from Taiwan and using the same NCEP-ATPIII definition, Liao et al [17] found that incident nondiabetic PD patients ( n = 280) with MS had poorer patient survival compared to those without MS for both total and cardiovascular event–free patient survival. Similarly, higher patient mortality was found in the nondiabetic Indian PD patients with MS compared to those without ( n = 163) [18] . Sample size variation may be an explanation for the different conclusions.…”

Section: Controversies About Ms In Pd Patientsmentioning

confidence: 79%

“…In Taiwan, Liao et al [17] found that the prevalence was 52.9% among all PD patients, and it was 39.4% when diabetics were excluded. However, Prasad et al [18] reported 51.3% among nondiabetic PD patients. Therefore, there is substantial variation between countries and ethnicity, but the overall impression is that the prevalence is substantially higher than that in the general population even when diabetics are excluded.…”

Section: Prevalence Of Ms In Pd Patientsmentioning

confidence: 96%

See 1 more Smart Citation

Metabolic syndrome and obesity in peritoneal dialysis

2016

Kidney Research and Clinical Practice

View full text Add to dashboard Cite

Metabolic syndrome (MS) refers to clustering of features related to increased risk of cardiovascular disease, which include obesity or central obesity, dyslipidemia, diabetes mellitus or insulin resistance, together with hypertension. The prevalence of MS in end-stage renal failure patients on peritoneal dialysis is quite common, ranging from 40% to 60%, depending on the population studied and the definition used. However, there are controversies about the clinical outcome of patients with MS, particularly in the area of obesity. Whether peritoneal dialysis predisposes patients to MS is another unsolved issue. Despite these controversies, preventing patients from developing MS is important, at least from a theoretical point of view.

show abstract

Section: Controversies About Ms In Pd Patientsmentioning

confidence: 79%

Section: Prevalence Of Ms In Pd Patientsmentioning

confidence: 96%

Metabolic syndrome and obesity in peritoneal dialysis

2016

Kidney Research and Clinical Practice

View full text Add to dashboard Cite

show abstract

“…A recent meta-analysis of eight studies with a total of 1273 ESRD patients demonstrated that patients with MetS have a higher risk of all-cause mortality compared to patients without metabolic syndrome [10]. However, these studies comprised mostly of Asian HD patients [11,12,13] and patients on peritoneal dialysis [14,15,16]. Only two prospective studies [17,18] investigated mortality in Caucasian HD patients with MetS.…”

Section: Introductionmentioning

confidence: 99%

Associations of Cardiovascular and All-Cause Mortality with Metabolic Syndrome in Hemodialysis Patients: A Prospective Single-Center Study

et al. 2019

View full text Add to dashboard Cite

Background and objectives: Metabolic syndrome (MetS) is a cluster of risk factors, such as abdominal obesity, insulin resistance, dyslipidemia and hypertension, that together increase the risk of cardiovascular disease. Chronic hemodialysis (HD) patients have multiple comorbidities and many metabolic disorders, causing the frequent occurrence of metabolic syndrome. The goal of this study was to assess the prevalence of MetS in HD patients, and its association with all-cause and cardiovascular (CV) mortality. Patients and methods: A total of 138 HD patients were included in this prospective study. We analyzed demographic, anthropometric and biochemical data. Outcome measures were all-cause and CV mortality during the three-year follow-up. Results: MetS was diagnosed in 57.24% of enrolled patients. During the 36 months of follow-up, 33 patients died. MetS patients showed a significantly higher mortality rate than non-MetS (30.4% versus 16.36%, p < 0.001). The association of different MetS components with cardiovascular mortality reached significance when a minimum of three components were present (1.81 (95% confidence interval CI = 1.21–2.33)), with a grouped increase in effect size for subjects with four or five MetS components. Subjects with MetS exhibited nearly twice as high risk for all-cause (hazard ratio HR = 1.99 (95%CI) = 1.42–2.97) and 2.5 times for CV (HR = 2.51 (95%CI) = 1.25–3.83) mortality compared with those without MetS, after adjustment for age, gender, and cardiovascular disease. Conclusions: The study demonstrates that MetS is widespread in HD patients. In future, the focus must be on an active screening approach, and treatment of cardiometabolic risk factors, aiming to reduce mortality.

show abstract

“…The rate of death due to cardiovascular disease reaches 40-50% in patients receiving renal replacement therapies 4 . Several studies have showed that peritoneal dialysis patients were more at risk for the development of dyslipidemia and hyperinsulinemia 5 , 6 .…”

Section: Introductionmentioning

confidence: 99%

Comparison of risk factors for cardiovascular disease in hemodialysis and peritoneal dialysis patients

Harmankaya¹,

Akalın²,

Akay³

et al. 2015

Clinics

View full text Add to dashboard Cite

OBJECTIVE:In this study, we aimed to compare the cardiovascular risk factors that might be associated with inflammation, atherosclerosis and metabolic syndrome between hemodialysis and peritoneal dialysis patients.METHODS:Fifty hemodialysis and 50 peritoneal dialysis patients who had been receiving dialysis therapy for at least one year were included in the study. Venous blood samples were taken after 12 hours of fasting, and serum glucose, triglyceride, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, C-reactive protein, fibrinogen and homocysteine levels were measured. The presence of atherosclerotic plaques in the carotid artery was evaluated by carotid Doppler ultrasound. These data were analyzed by Student's t test, the chi-square test and the Mann-Whitney U test, as appropriate.RESULTS:No difference was found between the hemodialysis (n=50) and peritoneal dialysis (n=50) patient groups regarding mean age, gender distribution, body mass index or dialysis duration (p=0.269, 0.683, 0.426, and 0.052, respectively). LDL-cholesterol, fibrinogen and homocysteine levels were significantly higher in peritoneal dialysis patients (p=0.006, 0.001, and 0.002, respectively). In patients with diabetes mellitus (n=17) who were undergoing renal replacement therapy, LDL-cholesterol and fibrinogen levels were significantly higher than in patients without diabetes mellitus who were undergoing renal replacement therapy (p=0.001 and 0.004, respectively).CONCLUSION:In our study, cardiovascular risk factors (especially LDL-cholesterol) were more frequent in peritoneal dialysis patients than in hemodialysis patients.

show abstract

Effect of metabolic syndrome on clinical outcomes of non‐diabetic peritoneal dialysis patients in India

Abstract: Prevalence of MS in non-diabetic PD patient is high and predicts long term patient and technique survival.

Cited by 12 publications

References 47 publications

Metabolic syndrome and obesity in peritoneal dialysis

Metabolic syndrome and obesity in peritoneal dialysis

Associations of Cardiovascular and All-Cause Mortality with Metabolic Syndrome in Hemodialysis Patients: A Prospective Single-Center Study

Comparison of risk factors for cardiovascular disease in hemodialysis and peritoneal dialysis patients

Contact Info

Product

Resources

About